ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 168

Allopurinol Use Is Associated with a Decreased Risk of Myocardial Infarction

Lamiae Grimaldi-Bensouda1, Annick Alpérovitch2, Elodie Aubrun1, Nicolas Danchin3, Michel Rossignol4, Lucien Abenhaim5, Pascal Richette6 and PGRx MI Group7, 1LA-SER, Paris, France, 2Inserm U708-Neuroepidemiology, La Pitié-Salpêtrière Hospital, Paris, France, 3Coronary disease unit, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris and Paris-Descartes University, Paris, France, 4LA-SER, Centre for Risk Research, Montreal, Canada, 5LA-SER Europe Ltd, London, United Kingdom, 6Lariboisière Hospital, Paris, France, 7Paris, France

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: gout

  • Tweet
  • Email
  • Print
Session Information

Session Title: Metabolic and Crystal Arthropathies

Session Type: Abstract Submissions (ACR)

Background/Purpose: Xanthine oxidase inhibitors (XOI) reduce both urate levels and the oxidative stress in the vasculature, which are known cardiovascular risk factors. However, the effects of XOI on major cardiac events such as myocardial infarction (MI) are unknown. The objective was to investigate whether XOI use is associated with a modified risk of myocardial infarction.

Methods: We used a matched case-control study comparing patients with first ever MI with controls. Cases were retrieved from a myocardial infarction registry consisting of 63 cardiology centers, whereas controls were selected from general practice settings. The association between XOI or colchicine use and MI was assessed by adjusted OR from conditional logistic regression.

Results: Data are from 2277 MI patients matched to 4849 controls. Allopurinol was by far the most frequent XOI taken by participants of this study. The adjusted OR (95% CI) for MI in allopurinol users was 0.75 (0.56-1.01), and it was 0.66 (0.49-0.89) using the whole pool of referents (n=8444). The effect of allopurinol persisted across subgroups by sex, presence of hypertension, and in ST-segment elevation MI patients. In contrast, colchicine use was not associated with a modified risk of MI: aOR= 1.17 (0.70-1.93).

Conclusion: Allopurinol, but not colchicine use, is associated with around a 30% reduction in the risk of myocardial infarction. Besides its urate lowering property, allopurinol might have a cardio protective effect.


Disclosure:

L. Grimaldi-Bensouda,
None;

A. Alpérovitch,
None;

E. Aubrun,
None;

N. Danchin,
None;

M. Rossignol,
None;

L. Abenhaim,
None;

P. Richette,
None;

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/allopurinol-use-is-associated-with-a-decreased-risk-of-myocardial-infarction/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies